Home > Products >

AlbuSorb™ LS
AlbuSorbâ„¢ LS Suspension Reagent


 
 
5
Base Price: $425.00


Product Code: -ALS385-25


Size (ALS385):

Qty:
Description
 

AlbuSorb™ LS

Suspension Reagent for Albumin Depletion From Serum or Plasma

  • Removes 30 mg albumin/ml, >90%
  • Affinity-type equivalence, virtually no cross-reactivity with other proteins
  • Disposable, no column regeneration or cross-contamination
  • Simpler alternative protocol to dry-bead AlbuSorb™ format
  • Suitable for 96-well, high-throughput and automation
  • Economical polymer technology, not based on blue-dye or immuno-affinity
  • Mild binding conditions maintains tertiary structure and seamless transfer to secondary analysis
  • The flow-through (unbound) fraction retains enzymatic and biological activity
  • Species agnostic, including human, sheep, bovine, mouse, goat, rat, and calf.

Poly-electrolytes are polymers with repeating units of stationary charges. AlbuSorb™ LS comes from a class of solid-phase, elastomeric poly-electrolytyes that bind proteins through an empirically derived chemistry combining elements of polymer composition, cross-linking architecture and charge properties. Unlike immuno-affinity, the solid-phase utilized is disposable, eliminating cycle to cycle variance and cross-contamination. AlbuSorb™ LS is supplied as a liquid suspension, so no weighing; simply pipette, centrifuge and/or filter, and recover the albumin depleted serum/plasma in the unbound fraction.

AlbuSorb™ LS is purchased as a suspension reagent with the binding buffer, and spin-filter assemblies. Additional spin-Filter assemblies (low protein binding, 0.45 µm filter element) can be purchased as accessories; please inquire. For larger preps, centrifugation can also be used without the need for filters; bulk quantities of AlbuSorb™ LS can be purchased, please inquire.

Click here to view AlbuSorb™ LS Suspension Reagent Product sheet
References

Exosome Chettimada, Sukrutha, et al. "Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy." Scientific Reports 8.1 (2018): 7227.

Cerebrospinal Fluid
Gwenael Pottiez, Pawel Ciborowski. Proteomic Profiling of Cerebrospinal Fluid Expression Profiling In Neuroscience Neuromethods.2012;64:245-270

Synovial fluid
Happonen KE, Fürst CM, Saxne T et al. PRELP protein inhibits the formation of the complement membrane attack complex.Journal of Biological Chemistry.2012;287(11):8092-100

Serum
Valladolid-Acebes, Ismael, et al. "Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements." Science Advances 7.11 (2021).

Increased levels of apolipoprotein CIII (apoCIII), result in obesity-related metabolic derangements. The researchers investigated mechanistically whether lowering or preventing high-fat diet (HFD)– induced increase in apoCIII, protects against the detrimental metabolic consequences. For Western blotting determination of circulating apoCIII, the article states, “plasma was albumin depleted using AlbuSorb according to the manufacturer’s protocol (Biotech Support Group LLC) and resuspended in 0.1% (v/v) trifluoroacetic acid.”

Nelson K, Wilkinson, S. et al., High resolution accurate mass spectrometry-based proteomics in ecotoxicology: SWATH-MS to detect differentially expressed plasma proteins in the amphibian toxicological model Xenopus laevis. Poster: Conference: PRIMO20, May 2019

Valladolid-Acebes, Ismael, et al. "Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements." Science Advances 7.11 (2021): eabc2931.

Holmberg R, Refai E, Höög A.Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proceedings of the National Academy of Sciences.2011;108(26):10685-9.

Tang MX, Ogawa K, Asamoto M. Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats Nutrition and Cancer.2011;63(2):227-33

Holmberg, Rebecka Apolipoprotein CIII and Ljungan virus in diabetes 2010. Doctoral Thesis

Lu Q, Zheng X, McIntosh T Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Analytical Chemistry.2009;81(21):8715-23

Cell/Tissue Culture Media

“AlbuSorb™ worked very well for us. We removed at least 90% of the albumin from our 10% FBS conditioned medium samples”, Joseph Sucic, University of Michigan.

Urine
Zubiri, Irene, et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. Journal of Proteomics (2013).

Patent
Berggren, Per Olaf, Yang, Shao-Nian. 2012. Methods For Treating And/Or Limiting Development Of Diabetes.U.S. Patent 20120328630 Kind Code: A1, filed June 25, 2012, and issued December 27, 2012.